Abstract: In one aspect, a method of confirming identity of an entity is disclosed. The method comprises receiving a plurality of items for delivery to an address, obtaining, from the items, information regarding an entity associated with the items and the address, and delivering the items to the address. The method may also comprise identifying an expected identity of the entity, receiving a request to confirm an identity of the entity using third-party identity verification via a user interface, and determining, based on the information regarding the entity, a confidence score for the expected identity. The method may further comprise determining whether the confidence score is greater than or equal to the threshold value and generating a response to the request. The method may additionally comprises displaying the response via the user interface.

Abstract: In one aspect, a method of confirming identity of an entity is disclosed. The method comprises receiving a plurality of items for delivery to an address, obtaining, from the items, information regarding an entity associated with the items and the address, and delivering the items to the address. The method may also comprise identifying an expected identity of the entity, receiving a request to confirm an identity of the entity using third-party identity verification via a user interface, and determining, based on the information regarding the entity, a confidence score for the expected identity. The method may further comprise determining whether the confidence score is greater than or equal to the threshold value and generating a response to the request. The method may additionally comprises displaying the response via the user interface.

Abstract: Compounds for inhibiting human epithelial 15-lipoxygenase-2 (h15-LOX-2) are provided. Compounds according to certain embodiments modulate ferroptosis and generation of hydroperoxy eicosatetraenoic acids (HpETEs). In some embodiments, compounds described herein modulate eicosanoid mediator biosynthesis from leukotrienes (LTs) to pro-resolving mediator class of lipoxins (LXs). Methods for treating or preventing a human epithelial 15-lipoxygenase-2(h15-LOX-2)-mediated disease are also provided. Compositions for practicing the subject methods are also described.

Abstract: Provided herein are, inter alia, methods and composition for the treatment of cancers that are recalcitrant to treatment and/or become resistant to certain drug treatments. The methods provided may, inter alia, be used to treat cancer in subjects having elevated STAT1 activity levels.

Abstract: Compounds for inhibiting human platelet-type 12-(S)-lipoxygenase (12-LOX) are provided. Compounds according to certain embodiments modulate platelet activation and hemostasis. In some embodiments, compounds described herein modulate platelet activation mediated by immune receptor, Fc?RIIa. Methods for modulating platelet reactivity (e.g., following vascular insult or injury) with the compounds are also described. Methods for treating or preventing a platelet-type 12-(S)-lipoxygenase (12-LOX)-mediated disease are also provided. Compositions for practicing the subject methods are also described.

Abstract: A method is provided for delivering radiation therapy to a patient. The method can include receiving a radiation treatment plan for the patient, receiving first imaging data, the first imaging data can be a dual-energy imaging acquisition, delivering a radiation therapy beam to a patient, receiving, from a portal imaging system, second imaging data, the portal imaging system can sense the radiation therapy beam to acquire the second imaging data, and compensating for movement of the patient, based on the first imaging data and the second imaging data.

Abstract: Extended field-of-view imaging is enabled by combined imaging with a kilovolt (“kV”) x-ray source and a megavolt (“MV”) x-ray source, in which at least one of the corresponding x-ray detectors is laterally offset from the target isocenter by an amount such that the x-ray detector does not have a view of the target isocenter. This scan geometry enables the reconstruction of non-truncated images without resorting to the more expensive solution of outfitting the imaging or radiotherapy system with enlarged x-ray detectors.

Abstract: Extended field-of-view imaging is enabled by combined imaging with a kilovolt (“kV”) x-ray source and a megavolt (“MV”) x-ray source, in which at least one of the corresponding x-ray detectors is laterally offset from the target isocenter by an amount such that the x-ray detector does not have a view of the target isocenter. This scan geometry enables the reconstruction of non-truncated images without resorting to the more expensive solution of outfitting the imaging or radiotherapy system with enlarged x-ray detectors.

Abstract: In one aspect, a method of confirming identity of an entity is disclosed. The method comprises receiving a plurality of items for delivery to an address, obtaining, from the items, information regarding an entity associated with the items and the address, and delivering the items to the address. The method may also comprise identifying an expected identity of the entity, receiving a request to confirm an identity of the entity using third-party identity verification via a user interface, and determining, based on the information regarding the entity, a confidence score for the expected identity. The method may further comprise determining whether the confidence score is greater than or equal to the threshold value and generating a response to the request. The method may additionally comprises displaying the response via the user interface.

Abstract: A medical food composition, containing at least source of milk protein derived from milk producing animals, exposed to immune stimulants during pregnancy and lactation period, source of Curcuminoids, source of proteolytic enzymes, and source of Piperin effective to manage inflammatory response and associated pain symptoms in mammals.